INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKGlobeNewsWire • 08/17/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of GSK plc – GSKGlobeNewsWire • 08/13/25
GSK secures $370 million settlement and future royalties in CureVac mRNA patent disputeProactive Investors • 08/08/25
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challengesWSJ • 08/01/25
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook RaiseZacks Investment Research • 07/30/25
GSK may have numbers may have been flattered by order timing, says bankProactive Investors • 07/30/25
GSK confident of hitting top end of 2025 targets after strong second quarterProactive Investors • 07/30/25
GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA ApprovalSeeking Alpha • 07/28/25
GSK to make $500m down payment on Chinese licensing deal worth up to $12bnProactive Investors • 07/28/25
Hengrui Pharma and GSK enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and OncologyPRNewsWire • 07/28/25
GSK sponsors 2025 National Senior Games as part of Sideline RSV campaign to raise awareness of RSV in older adultsBusiness Wire • 07/24/25